CRISPR Therapeutics Files For $90 Mln IPO

(RTTNews) - CRISPR Therapeutics AG, which is developing cures for genetic diseases based on CRISPR-Cas9 technology, has filed with the U.S. Securities and Exchange Commission for an initial public offering of up to $90 million of common stock. No pricing terms were disclosed.

The company said that it has applied to list its common stock on the NASDAQ Global Market under the trading symbol "CRSP".

The Basel, Switzerland-based company was founded in 2013 and booked $2 million in sales for the 12 months ended June 30, 2016.

For the six months ended June 30, 2016, the company reported collaboration revenue of $1.3 million and a loss of $4.66 per share.

Citi, Piper Jaffray, Barclays and Guggenheim Securities are the joint bookrunners on the deal.